The PRECEDE Consortium Study

The PRECEDE Consortium is an observational longitudinal prospective cohort study to change the survival rate of pancreatic cancer through early detection!

[The PRECEDE Consortium Study @PrecedeStudy]

#WorldCancerDay2022 So incredibly grateful to all our collaborators in early detection for pancreatic cancer! Special thanks to @katebolduan and our amazing patients for sharing their stories! We have a lot of work to do!! #earlydetectionpancreaticcancer

https://t.co/SK9ANucTBn

[PanCAN @PanCAN]

#Thanksgiving gatherings could be the right time to start a conversation about the importance of testing for #pancreaticcancer with your family. 💜🦃 Two genetic counselors give you some tips on how to make it a useful, productive discussion: https://t.co/3IUopSj85P

[The PRECEDE Consortium Study @PrecedeStudy]

Future looks bright for pancreatic cancer! #flbpc #flb4pc #precedestudy @MadameSurgeon #lattice @AmbryGenetics

[The PRECEDE Consortium Study @PrecedeStudy]

PRECEDE: The future looks bright for pancreatic cancer #realmidx @AmbryGenetics #precede #trovanow @MadameSurgeon

[The PRECEDE Consortium Study @PrecedeStudy]

@MadameSurgeon spoke with @OncoZine & @AmbryGenetics CEO Tom Schoenherr about our international collaboration to transform early detection & prevention of pancreatic cancer. Learn more: https://t.co/pAoKLOjtxy #precedestudy #precedeconsortium #pancreaticcancerawarenessmonth

[The PRECEDE Consortium Study @PrecedeStudy]

So sad to hear about this! Our hearts go out to Willie’s family and loved ones. Early detection is so important before we lose another star to pancreatic cancer! #earlydetection #precedestudy #precedeconsortium

https://t.co/mrkmWAgq86

[The PRECEDE Consortium Study @PrecedeStudy]

KMPM announces a new name to reflect their focus on integrated diagnostics for multi-modal and multi-omics data! So excited to be collaborating on this whole new realm of possibilities! #earlydetection #precedeconsortium #precedestudy

https://t.co/VXLN2ZtDkL

[The PRECEDE Consortium Study @PrecedeStudy]

Dr. Diane Simeone shares new information regarding the PALB2 mutation in breast and pancreatic cancer risk
@MadameSurgeon #earlydetection #PancreaticCancer #breastcancer #genetictesting @AmbryGenetics
https://t.co/aIztUFLRWO

[Diane M. Simeone, MD @MadameSurgeon]

New information highlighting the link between PALB2 and breast and pancreatic cancer risk- the latest data about the value of pancreatic cancer screening in this setting
#earlydetection #PancreaticCancer #breastcancer @AmbryGenetics @PrecedeStudy
https://t.co/1EMPFNhwuo

[The PRECEDE Consortium Study @PrecedeStudy]

A message from the Principal Investigator for PRECEDE Consortium Study, Dr. Diane Simeone.
https://t.co/XUGgzCMEFw

https://t.co/xdonjBhxS3

[Diane M. Simeone, MD @MadameSurgeon]

Exciting collaboration w. PRECEDE and KMPM for early detection of pancreatic cancer! Bringing hope to all affected by this disease! #earlydetectionpancreaticcancer #precedestudy @AmbryGenetics @PrecedeStudy @Trova_now
https://t.co/YzjmPHXuXj

[The PRECEDE Consortium Study @PrecedeStudy]

Hope for pancreatic cancer through early detection is finally here! So grateful to KMPM! #earlydetection #precedestudy #precedeconsortium #trovanow @KonicaMinoltaUS @konicaminolta @Trova_now
https://t.co/RBHCRS04A1